马萨诸塞州沃本 -- （美国商业资讯） -- 处于合成生物学前沿的综合性生命科学公司Abpro于4月6日宣布，与总部在中国的生物制药公司亿胜生物科技缔结伙伴关系。Abpro将发挥Abpro的DiversImmune?平台的优势，与亿胜合作开发免疫肿瘤科和眼科领域的多个单克隆抗体。

Business combination closed November 13, 2024 Raised $10 million of gross proceeds in connection with the business combination Agreements are in place with Yorkville for up to a $50 million standby ...

BURLINGTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Abpro Corporation (Nasdaq: ABP) (“Abpro”) and Celltrion, Inc. (“Celltrion”) today announced that they will present new preclinical data for ...